XML 38 R10.htm IDEA: XBRL DOCUMENT v3.25.4
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2025
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

During the quarter ended December 31, 2025, three of our executive officers adopted Rule 10b5-1 trading plans, which are set forth in the table below.

 

Name and Position

 

Action

 

Adoption/
Termination
Date

 

Rule 10b5-1(1)

 

Non-Rule
10b5-1(2)

 

Total Shares of
Common Stock
to be Sold

 

 

Expiration
Date

Robert Lechleider, Chief Medical Officer

 

Adoption

 

December 24, 2025

 

X

 

 

 

 

110,000

 

 

December 31, 2026

Jack Higgins, Chief Scientific Officer

 

Adoption

 

December 19, 2025

 

X

 

 

 

 

37,729

 

 

December 31, 2026

Max Rosett, Chief Financial Officer

 

Adoption

 

December 26, 2025

 

X

 

 

 

 

125,000

 

 

September 30, 2026

 

(1)
Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
(2)
"Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.
Robert Lechleider  
Trading Arrangements, by Individual  
Name Robert Lechleider
Title Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 24, 2025
Expiration Date December 31, 2026
Aggregate Available 110,000
Jack Higgins  
Trading Arrangements, by Individual  
Name Jack Higgins
Title Chief Scientific Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 19, 2025
Expiration Date December 31, 2026
Aggregate Available 37,729
Max Rosett  
Trading Arrangements, by Individual  
Name Max Rosett
Title Chief Financial Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 26, 2025
Expiration Date September 30, 2026
Aggregate Available 125,000